TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9031709

Group type: EXPERIMENTAL
Intervention: Alpha brainwave training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Beta (mock) brainwave training
Number of subjects: 20
Study: 1734558

Group type: EXPERIMENTAL
Intervention: Continuous nasogastric feeding
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intermittent feeding (1-hourly, 2-hourly, 3-hourly)
Number of subjects: 18
Study: 6143868

Group type: EXPERIMENTAL
Intervention: 3 micrograms heat-inactivated hepatitis B vaccine at birth and at 1, 2, and 6 months, plus seven monthly HBIg injections
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 3 micrograms heat-inactivated hepatitis B vaccine at birth and at 1, 2, and 6 months, plus one HBIg injection at birth
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Only the vaccine at months 0, 1, 2, and 6
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebos for both vaccine and HBIg
Number of subjects: 140
Study: 3525266

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Intensive conventional insulin therapy (ICT)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: ICT
Number of subjects: 39
Study: 30810465

Group type: EXPERIMENTAL
Intervention: Machine learning model for predicting recurrent urinary tract infection associated vesicoureteral reflux
Number of subjects: 500

Group type: COMPARATOR
Intervention: Voiding cystourethrogram
Number of subjects: 500
Study: 29031905

Group type: EXPERIMENTAL
Intervention: Tesamorelin, 2mg daily for six months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tesamorelin
Number of subjects: 50
Study: 25517477

Group type: EXPERIMENTAL
Intervention: Long-axis view
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Long-axis view for subclavian
Number of subjects: 28

Group type: COMPARATOR
Intervention: Short-axis view
Number of subjects: 28
Study: 23861293

Group type: EXPERIMENTAL
Intervention: 150 min/wk aerobic exercise for 4 months
Number of subjects: 141

Group type: COMPARATOR
Intervention: No-exercise control
Number of subjects: 141
Study: 21223629

Group type: EXPERIMENTAL
Intervention: Midazolam alone
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Midazolam plus remifentanil
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sedated patients (midazolam or midazolam plus remifentanil)
Number of subjects: 59
Study: 19916292

Group type: EXPERIMENTAL
Intervention: Acupoint-catgut implantation (once every two weeks for the first 6 treatments, then once a month for 1 year)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Massage (20 mm, once daily for 1 year)
Number of subjects: 68
Study: 16491584

Group type: EXPERIMENTAL
Intervention: Room air breathing during tilt
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 5% inhaled CO2 during tilt
Number of subjects: 30
Study: 15270743

Group type: EXPERIMENTAL
Intervention: Triple therapy with lansoprazole plus amoxicillin and tinidazole
Number of subjects: 43

Group type: COMPARATOR
Intervention: Dual therapy with amoxicillin and tinidazole
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: H. pylori-positive children
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: H. pylori-negative children
Number of subjects: 43
Study: 11375363

Group type: EXPERIMENTAL
Intervention: Total-contact casts (TCC)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Removable cast walkers (RCW)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Half-shoes
Number of subjects: 63
Study: 8995552

Group type: EXPERIMENTAL
Intervention: 0.06 mg/m2 rhTNF‐alpha intraperitoneally after drainage of fluid
Number of subjects: 39

Group type: COMPARATOR
Intervention: Drainage alone
Number of subjects: 39
Study: 8353072

Group type: EXPERIMENTAL
Intervention: Standard dose chemotherapy (cyclophosphamide 600 mg/m2, carboplatin 300 mg/m2, adriamycin 50 mg/m2, ifosfamide 5 G/m2) for 6 cycles at monthly intervals
Number of subjects: 99

Group type: COMPARATOR
Intervention: Half dose chemotherapy (cyclophosphamide 300 mg/m2, carboplatin 150 mg/m2, adriamycin 25 mg/m2, ifosfamide 2.5 G/m2) for 12 cycles at monthly intervals
Number of subjects: 99

Group type: COMPARATOR
Intervention: Half dose chemotherapy (300 mg/m2 cyclophosphamide and 150 mg/m2 carboplatin) for 12 cycles
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Standard dose chemotherapy (600 mg/m2 cyclophosphamide and 300 mg/m2 carboplatin) for 6 cycles
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Both standard and low dose cycles of chemotherapy
Number of subjects: 99
Study: 3301453

Group type: EXPERIMENTAL
Intervention: Epomediol (200 mg three times daily for 30 days)
Number of subjects: 519

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 519
Study: 29104179

Group type: EXPERIMENTAL
Intervention: Six-month dual antiplatelet therapy (DAPT)
Number of subjects: 1368

Group type: COMPARATOR
Intervention: 12-month dual antiplatelet therapy (DAPT)
Number of subjects: 1368

Group type: EXPERIMENTAL
Intervention: Six-month DAPT
Number of subjects: 1368
Study: 28426355

Group type: EXPERIMENTAL
Intervention: CBT plus CM (voucher-based contingency management)
Number of subjects: 92

Group type: COMPARATOR
Intervention: CBT
Number of subjects: 92
Study: 25692915

Group type: EXPERIMENTAL
Intervention: Aflibercept (2.0 mg)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Bevacizumab (1.25 mg)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.3 mg)
Number of subjects: 660

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 660
Study: 23746564

Group type: EXPERIMENTAL
Intervention: Bicarbonate loading (300 mg∙kg⁻¹)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo ingestion
Number of subjects: 11
Study: 21344002

Group type: EXPERIMENTAL
Intervention: 2% PRO2000/5 microbicide gel
Number of subjects: 250
Study: 18267977

Group type: EXPERIMENTAL
Intervention: Short intravenous treatment (3 days of intravenous ceftriaxone followed by 5 days of oral antibiotics)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Long intravenous treatment (8 days of intravenous ceftriaxone)
Number of subjects: 383
Study: 16584432

Group type: EXPERIMENTAL
Intervention: PCT apheresis PLTs
Number of subjects: 2237

Group type: EXPERIMENTAL
Intervention: CAD treatment
Number of subjects: 2237

Group type: COMPARATOR
Intervention: Untreated apheresis PLTs
Number of subjects: 2237
Study: 14638556

Group type: EXPERIMENTAL
Intervention: Always active
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Inconsistently active
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Always inactive
Number of subjects: 229
Study: 11096148

Group type: EXPERIMENTAL
Intervention: Once weekly subcutaneous epoetin beta (n=118)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Two or three times weekly subcutaneous epoetin beta (control group, n=40)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Once weekly subcutaneous epoetin beta
Number of subjects: 158

Group type: COMPARATOR
Intervention: Two or three times weekly subcutaneous epoetin beta (control group)
Number of subjects: 158
Study: 9263161

Group type: EXPERIMENTAL
Intervention: Prestructured pain behavior assessment in Study 2
Number of subjects: 45

Group type: COMPARATOR
Intervention: Descriptive assessments of behavior in Study 1
Number of subjects: 45
Study: 8323238

Group type: EXPERIMENTAL
Intervention: Closed suction drainage for 12 hours
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Closed suction drainage for 24 hours
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Closed suction drainage for 48 hours
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no suction drainage)
Number of subjects: 60
Study: 3092084

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31460597

Group type: EXPERIMENTAL
Intervention: Oral health promotion program (intervention group)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Usual care from bariatric clinic staff (control group)
Number of subjects: 109
Study: 29268886

Group type: EXPERIMENTAL
Intervention: Switched dual antiplatelet therapy (DAPT)
Number of subjects: 645

Group type: COMPARATOR
Intervention: Unchanged dual antiplatelet therapy (DAPT)
Number of subjects: 645
Study: 25844616

Group type: EXPERIMENTAL
Intervention: Topical epidermal growth factor (EGF) serum applied twice daily for 12 weeks
Number of subjects: 18
Study: 23129056

Group type: EXPERIMENTAL
Intervention: HRV biofeedback (BIO)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Comparative group (COM)
Number of subjects: 18
Study: 21813548

Group type: EXPERIMENTAL
Intervention: CDAI
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: SDAI
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: DAS28
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: DAS28-CRP
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: ACR/EULAR remission criteria
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Generalized Estimating Equations analyses
Number of subjects: 508
Study: 19003590

Group type: EXPERIMENTAL
Intervention: Selective photodynamic therapy (PDT) using an optic fiber with an 810‐nm diode laser after indocyanine green (ICG) application
Number of subjects: 5
Study: 16442904

Group type: EXPERIMENTAL
Intervention: TEE-guided strategy
Number of subjects: 1222

Group type: EXPERIMENTAL
Intervention: TEE-guided strategy (direct current cardioversion)
Number of subjects: 1222

Group type: COMPARATOR
Intervention: Conventional strategy
Number of subjects: 1222

Group type: COMPARATOR
Intervention: Conventional strategy (direct current cardioversion)
Number of subjects: 1222
Study: 15215810

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment combined with streptokinase
Number of subjects: 74

Group type: COMPARATOR
Intervention: Streptokinase alone
Number of subjects: 74
Study: 10842419

Group type: EXPERIMENTAL
Intervention: Combination of 400 mg of vitamin E and 500 mg of vitamin C
Number of subjects: 22

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 22
Study: 9219199

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.3 g.kg‐1)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Breathing 100% O2
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 6
Study: 8378411

Group type: EXPERIMENTAL
Intervention: Maprotiline (up to 75 mg/d)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 3010516

Group type: EXPERIMENTAL
Intervention: LAV enzyme immunoassay (EIA)
Number of subjects: 1406

Group type: COMPARATOR
Intervention: HTLV-III EIA
Number of subjects: 1406

Group type: EXPERIMENTAL
Intervention: Western blot
Number of subjects: 1406

Group type: EXPERIMENTAL
Intervention: LAV EIA and HTLV-III EIA
Number of subjects: 1406

Group type: EXPERIMENTAL
Intervention: LAV EIA
Number of subjects: 1406
Study: 29494784

Group type: EXPERIMENTAL
Intervention: Cognitive-Functional (Cog-Fun) intervention
Number of subjects: 107

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 107
Study: 27409565

Group type: EXPERIMENTAL
Intervention: HAS-BLED score
Number of subjects: 2283

Group type: COMPARATOR
Intervention: ORBIT score
Number of subjects: 2283
Study: 25336079

Group type: EXPERIMENTAL
Intervention: Supervised mask use
Number of subjects: 164

Group type: COMPARATOR
Intervention: No supervised mask use (control)
Number of subjects: 164
Study: 22471126

Group type: EXPERIMENTAL
Intervention: Auricular stimulator in the cavum concha for 30 min, once daily for 3 months
Number of subjects: 45
Study: 19834313

Group type: EXPERIMENTAL
Intervention: Metformin (1 g b.d, n=26)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Oral contraceptive pill (OCP) (35 g ethinyl estradiol/2 mg cyproterone acetate, n=30)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (women without PCOS, n=27)
Number of subjects: 107
Study: 18030228

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg once daily for 8 weeks
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily for 8 weeks
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg and 40 mg once daily for 8 weeks
Number of subjects: 148
Study: 15803017

Group type: EXPERIMENTAL
Intervention: Granisetron (40 microg/kg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ondansetron (0.1 mg/kg)
Number of subjects: 22
Study: 11871213

Group type: EXPERIMENTAL
Intervention: Low-fat/high simple carbohydrate diet
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Low-fat/high complex carbohydrate diet
Number of subjects: 398

Group type: COMPARATOR
Intervention: Control diet group with normal macronutrient intake
Number of subjects: 398

Group type: COMPARATOR
Intervention: Seasonal control group
Number of subjects: 398
Study: 10195516

Group type: EXPERIMENTAL
Intervention: 0.1 mL/kg 1% lidocaine i.v.
Number of subjects: 100

Group type: COMPARATOR
Intervention: 0.1 mL/kg isotonic sodium chloride solution (placebo control)
Number of subjects: 100
Study: 7760868

Group type: EXPERIMENTAL
Intervention: GM‐CSF (5 micrograms per kilogram of body weight per day intravenously over a period of six hours)
Number of subjects: 388

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 388
Study: 1994608

Group type: EXPERIMENTAL
Intervention: Percutaneous deflation prior to emergency tube decompression followed electively by colopexy with banding (n = 20)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Emergency tube decompression followed electively by sigmoid colectomy (n = 21)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Colopexy by banding
Number of subjects: 41

Group type: COMPARATOR
Intervention: Both elective procedures (colopexy and sigmoid colectomy)
Number of subjects: 41
Study: 6140939

Group type: EXPERIMENTAL
Intervention: Prizidilol hydrochloride (400 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30702971

Group type: EXPERIMENTAL
Intervention: Celecoxib with neoadjuvant chemotherapy (NAC)
Number of subjects: 156
Study: 29339565

Group type: EXPERIMENTAL
Intervention: Minding the Baby (MTB) home visiting program
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 158
Study: 24335026

Group type: EXPERIMENTAL
Intervention: Metformin (250 mg 3 times a day for 7 days)
Number of subjects: 152
Study: 22972538

Group type: EXPERIMENTAL
Intervention: Delayed-release doxylamine-pyridoxine (Diclectin)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study: 19605828

Group type: EXPERIMENTAL
Intervention: Endoscopic harvesting
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Open harvesting
Number of subjects: 3000
Study: 17395756

Group type: EXPERIMENTAL
Intervention: High-amount/vigorous-intensity exercise
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Low-amount/vigorous-intensity exercise
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Low-amount/moderate-intensity exercise
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control (inactivity)
Number of subjects: 240
Study: 15460211

Group type: EXPERIMENTAL
Intervention: Ibuprofen lysine (IbuLys) 400 mg (two tablets of Dolormin as a single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibuprofen (Ibu) 400 mg (two tablets as a single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (Plc)
Number of subjects: 0
Study: 11433224

Group type: EXPERIMENTAL
Intervention: VPA-985 (50 or 100 mg twice daily)
Number of subjects: 11
Study: 9460566

Group type: EXPERIMENTAL
Intervention: Abbott Cell Dyn 4000 (CD4000)
Number of subjects: 695

Group type: COMPARATOR
Intervention: FACScan
Number of subjects: 695

Group type: COMPARATOR
Intervention: Sysmex R1000
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: CD4000 IRF
Number of subjects: 695
Study: 8179848

Group type: EXPERIMENTAL
Intervention: Nebivolol (1, 5, or 10 mg)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (12.5 or 25 mg)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Combination of nebivolol and hydrochlorothiazide
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Nebivolol 10 mg combined with hydrochlorothiazide 25 mg
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 3069520

Group type: EXPERIMENTAL
Intervention: 600 mg choline theophyllinate administered orally every 12 h for 7 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: 300 mg anhydrous theophylline administered orally every 12 h for 7 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: 300 mg anhydrous theophylline
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 600 mg choline theophyllinate
Number of subjects: 18
Study: 29648853

Group type: EXPERIMENTAL
Intervention: SBIP plus IMP
Number of subjects: 160

Group type: COMPARATOR
Intervention: SBIP
Number of subjects: 160
Study: 25824436

Group type: EXPERIMENTAL
Intervention: Esophageal-directed hypnotherapy (EHYP) - 7 weekly sessions
Number of subjects: 0
Study: 24964299

Group type: EXPERIMENTAL
Intervention: Propofol (Group P)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ketamine (Group K)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Remifentanil (both groups)
Number of subjects: 40
Study: 22746968

Group type: EXPERIMENTAL
Intervention: Autonomous training with feedback from simulated patients and peers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional training with supervising physician
Number of subjects: 0

Group type: COMPARATOR
Intervention: Online training based on video fragments
Number of subjects: 0
Study: 19889113

Group type: EXPERIMENTAL
Intervention: Pre-emptive fentanyl 25 microg (0.5 ml) 1 min before administration of fentanyl 125 microg
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Pre-emptive fentanyl 25 microg (0.5 ml) 1 min before administration of fentanyl 150 microg
Number of subjects: 600

Group type: COMPARATOR
Intervention: Saline 0.9% (0.5 ml) 1 min before administration of fentanyl 150 microg
Number of subjects: 600
Study: 19034284

Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiotherapy for colorectal cancer
Number of subjects: 2481
Study: 16150800

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at 15 mmHg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at 35 mmHg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Baseline (0 mmHg LBNP)
Number of subjects: 8
Study: 13129460

Group type: EXPERIMENTAL
Intervention: Coconut flour (200-250 g/kg) in macaroons
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Coconut flour (200-250 g/kg) in carrot cake
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Coconut flour (150 g/kg) in test foods
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Coconut flour (50 g/kg) in pan de sal
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Coconut flour (100 g/kg) in multigrain loaf
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Coconut flour (50 g/kg) in granola bar
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Coconut flour (100 g/kg) in cinnamon bread
Number of subjects: 20
Study: 10814909

Group type: EXPERIMENTAL
Intervention: MIDCAB
Number of subjects: 150

Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 150
Study: 8690829

Group type: EXPERIMENTAL
Intervention: Imipramine (IMI)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mirtazapine (MIR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (age-matched controls)
Number of subjects: 20
Study: 1626680

Group type: EXPERIMENTAL
Intervention: Glycopyrronium 5 micrograms.kg‐1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Glycopyrronium 0 (Control)
Number of subjects: 20
Study: 6100497

Group type: COMPARATOR
Intervention: Low dose methotrexate regime (three cycles of etoposide, adriamycin and methotrexate at conventional dosage)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: High dose methotrexate regime (three cycles of etoposide and adriamycin with five courses of high dose methotrexate and folinic acid rescue)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Complete responders
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Partial responders
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Alternative four drug regime (procarbazine, vincristine, cyclophosphamide and CCNU)
Number of subjects: 83
Study: 31161374

Group type: EXPERIMENTAL
Intervention: CT-guided 125I brachytherapy (group A)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Supportive and symptomatic treatments (group B)
Number of subjects: 95
Study: 29590046

Group type: EXPERIMENTAL
Intervention: Dietary fibers promoting SCFA-producing strains
Number of subjects: 0
Study: 27122359

Group type: EXPERIMENTAL
Intervention: Internet program-DirectLife (Philips) aimed at increasing physical activity with monitoring and feedback by accelerometry and digital coaching
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Internet program-DirectLife (Philips) for participants who reached physical activity target
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Increase in minutes spent in moderate-to-vigorous physical activity (MVPA)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 235
Study: 24495481

Group type: EXPERIMENTAL
Intervention: Adjuvant cisplatin-based chemotherapy
Number of subjects: 524

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 524
Study: 22274684

Group type: EXPERIMENTAL
Intervention: Lansoprazole (15 mg/d if <30 kg; 30 mg/d if ≥30 kg)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 306
Study: 20861834

Group type: EXPERIMENTAL
Intervention: Enrichment-window strategy applied before standard statistical analysis
Number of subjects: 1837

Group type: COMPARATOR
Intervention: Traditional multicenter randomized clinical trials (RCTs)
Number of subjects: 1837
Study: 17923420

Group type: EXPERIMENTAL
Intervention: Nurses who reported at least one sharps injury; 49.6% recalled at least one sharps injury (95% CI 47.1%-52.1%).
Number of subjects: 2118

Group type: EXPERIMENTAL
Intervention: Nurses who reported sustaining between 1 and 4 injuries; 75.6% recalled this (95% CI 71.1%-79.6%).
Number of subjects: 2118

Group type: COMPARATOR
Intervention: Registered nurses and midwives compared to nurse managers; OR 1.6 (95% CI 1.1-2.3) for registered nurses, OR 2.4 (95% CI 1.4-3.9) for midwives.
Number of subjects: 2118

Group type: COMPARATOR
Intervention: Nurses with a previous contaminated NSI; OR 0.3 (95% CI 0.2-0.4).
Number of subjects: 2118